Ultrahuman raised a $70 million round led by Qualcomm Ventures on September 3, 2026, valuing the Indian wearables startup at $365 million as it works with Qualcomm on a future ring that runs on-device AI rather than just tracking sleep and recovery.
The FDA's new TEMPO pilot lets four digital health companies, including Limbic's AI voice therapy agent Unpacked, reach Medicare patients and gather real-world outcomes data before seeking full marketing authorization.
NVIDIA and Eli Lilly are investing up to $1 billion over five years in a San Francisco Bay Area AI co-innovation lab that pairs robotic wet labs with NVIDIA's BioNeMo and Vera Rubin computing platforms to run round-the-clock drug experiments.
Boston-based Elucid raised $55 million in an oversubscribed Series D, pushing total funding to roughly $185 million, to scale its FDA-cleared Plaque-IQ software and push its BioIntegrated FFR-CT tool through regulatory review.
A September 2026 review found fewer than a third of 903 FDA-authorized AI medical devices were validated on sex-specific populations, and as of this year developers can still win clearance without proving their tools perform equally for women.
Medtronic announced a roughly $700 million partnership with Cornerstone Robotics on September 1, 2026, taking distribution rights to its Sentire surgical system in select markets even as Medtronic's own Hugo robot expands to 35-plus countries.
MIT and Harvard researchers published an AI system called xvr in Nature on September 16, 2026, that matches a live surgical X-ray to a patient's pre-op 3D scan with sub-millimeter precision, outperforming existing methods by an order of magnitude.
Novo Nordisk announced on September 17, 2026 that it will deploy Anthropic's Claude Science across its research workflows, its second major AI drug-discovery tie-up this year after an April deal with OpenAI.
The FDA cleared Aidoc's CARE foundation-model AI to flag 14 acute abdominal conditions from one CT scan, with a pivotal study showing up to 98.5% sensitivity, as hospitals race to cut emergency-department imaging backlogs.
Paige, the digital pathology company acquired by Tempus in 2024, has secured FDA Breakthrough Device designation for PanCancer Detect, an AI tool that flags suspicious tissue across multiple organ sites and has already shown double-digit gains in detection accuracy in clinical testing.